Literature DB >> 27326011

Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease.

S Bleda1, J De Haro1, A Florez1, C Varela1, L Esparza1, F Acin1.   

Abstract

OBJECTIVES: Peripheral arterial disease can be regarded as a systemic inflammatory disorder affecting the entire vascular system. In the early clinical stages, it is characterised by the deterioration of endothelial function, which does not progress with the development of the disease. This study analyses the pleiotropic effects upon the plasma nitrite and C-reactive protein (CRP) levels in claudicating patients after 12 months of treatment with statins. STUDY
DESIGN: A prospective randomised controlled translational study was made in patients with Fontaine grade II ischaemia, treated with the best medical treatment with or without statins for 12 months from the time of diagnosis for assessing the pleiotropic effects of those statins.
METHODS: Measurements of plasma high-sensitivity CRP (hsCRP), lipid profile and nitrites were made at baseline and after 1 month and 1 year of treatment with atorvastatin 40 mg/day.
RESULTS: A significant reduction in nitrite levels was observed after 1 month of treatment (11.8±7.8 μM vs 5.7±1.8 μM, p=0.0001), but this effect did not persist after 1 year (11.8±7.8 μM vs 9.4±8.9 μM, p=0.27). HsCRP underwent a significant reduction after both 1 month (7 (2.2-12) vs 3.4 (1.6-5.5), p<0.01) and 1 year of treatment with atorvastatin (7 (2.2-12) vs 2.25 (1.67-6.7), p=0.02). Statin treatment reduced hsCRP levels in 9.64 (95% CI (1.60 to 17.68)) after 1 month and in 9.14 (95% CI (0.18 to 18.47)) after 1 year.
CONCLUSIONS: The long-term biological pleiotropic effects of statins provide information on the role of endothelial function and systemic inflammation in the aetiopathogenesis of peripheral arterial disease. Statins slow endothelial degradation at the start of the disease, with no effects over the long term. These drug substances reduce progressive inflammation throughout the treatment period. This supports the novel hypothesis that endothelial dysfunction is only a disease-triggering phenomenon, while systemic inflammation would be responsible for both the origin and the maintenance of peripheral arterial disease.

Entities:  

Keywords:  Endothelium; aorta; endothelial function; gene therapy; great vessels and trauma; peripheral vascular disease

Year:  2011        PMID: 27326011      PMCID: PMC4898577          DOI: 10.1136/heartasia-2011-010045

Source DB:  PubMed          Journal:  Heart Asia        ISSN: 1759-1104


  29 in total

1.  Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group.

Authors:  A B Newman; L Shemanski; T A Manolio; M Cushman; M Mittelmark; J F Polak; N R Powe; D Siscovick
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.

Authors:  A H Wagner; T Köhler; U Rückschloss; I Just; M Hecker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-01       Impact factor: 8.311

Review 4.  Nitric oxide as a signaling molecule in the vascular system: an overview.

Authors:  L J Ignarro; G Cirino; A Casini; C Napoli
Journal:  J Cardiovasc Pharmacol       Date:  1999-12       Impact factor: 3.105

5.  Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range.

Authors:  S Eda; J Kaufmann; W Roos; S Pohl
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

6.  HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells.

Authors:  Yoshiyuki Hattori; Nobuo Nakanishi; Kazumi Akimoto; Mika Yoshida; Kikuo Kasai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

7.  Relationship between the plasma concentration of C-reactive protein and severity of peripheral arterial disease.

Authors:  Joaquin De Haro; Francisco Acin; Francisco Jose Medina; Alfonso Lopez-Quintana; Jose Ramon March
Journal:  Clin Med Cardiol       Date:  2008-12-23

8.  Nitric oxide: link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs.

Authors:  Joaquin de Haro Miralles; Esther Martínez-Aguilar; Aurora Florez; César Varela; Silvia Bleda; Francisco Acin
Journal:  Interact Cardiovasc Thorac Surg       Date:  2009-04-17

9.  Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Toru Miyoshi; Yuhua Li; Diana M Shih; Xuping Wang; Victor E Laubach; Alan H Matsumoto; Gregory A Helm; Aldons J Lusis; Weibin Shi
Journal:  Life Sci       Date:  2006-03-03       Impact factor: 5.037

10.  Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein.

Authors:  Seiichi Kobayashi; Nobutaka Inoue; Yoshitaka Ohashi; Mitsuyoshi Terashima; Kiyoko Matsui; Takao Mori; Hideki Fujita; Kojiro Awano; Katsuya Kobayashi; Hiroshi Azumi; Junya Ejiri; Ken-ichi Hirata; Seinosuke Kawashima; Yoshitake Hayashi; Hiroshi Yokozaki; Hiroshi Itoh; Mitsuhiro Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-12       Impact factor: 8.311

View more
  3 in total

1.  Improving Total-Cholesterol/HDL-Cholesterol Ratio Results in an Endothelial Dysfunction Recovery in Peripheral Artery Disease Patients.

Authors:  Silvia Bleda; Joaquín de Haro; César Varela; Leticia Esparza; Javier Rodriguez; Francisco Acin
Journal:  Cholesterol       Date:  2012-09-25

2.  A Network-Biology Informed Computational Drug Repositioning Strategy to Target Disease Risk Trajectories and Comorbidities of Peripheral Artery Disease.

Authors:  Khader Shameer; Garrett Dow; Benjamin S Glicksberg; Kipp W Johnson; Yi Ze; Max S Tomlinson; Ben Readhead; Joel T Dudley; Iftikhar J Kullo
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2018-05-18

Review 3.  Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications.

Authors:  Armita Mahdavi Gorabi; Nasim Kiaie; Saeideh Hajighasemi; Maciej Banach; Peter E Penson; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Clin Med       Date:  2019-11-22       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.